Drug Profile
Research programme: cannabidiol-based therapeutics - Neuropathix
Alternative Names: Cannabinoid-based antioxidants - Neuropathix; Cannabinoid-based neuroprotectants - NeuropathixLatest Information Update: 28 Jan 2022
Price :
$50
*
At a glance
- Originator KannaLife Sciences
- Developer Neuropathix
- Class Anti-inflammatories; Benzene derivatives; Cannabinoids; Neuroprotectants; Small molecules
- Mechanism of Action Antioxidants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Brain injuries
Most Recent Events
- 28 Jan 2022 No recent reports of development identified for preclinical development in Brain injuries in USA
- 31 Dec 2021 Neuropathix has patents pending, patends abandone, patents expired and patents issued for inflammation, pain radiation dermatitis, skin disorders, hepatic encephalopathy in US, Japan, China, Belgium, Denamrk, Germany, in Ireland, Italy, in the Netherlands, in Spain, in Switzerland, France, in Turkery, in the UK, Europe, Macao, Australia, India, Russia Canada as of December 2021
- 19 Jun 2020 Kannalife plans to submit NDA for KLS 13023